Aoxing Pharma and Phoenix PharmaLabs to co-develop novel molecules for pain and drug addiction

7 June 2010

US companies Aoxing Pharmaceutical and Phoenix PharmaLabs have entered into a co-development, manufacturing and license agreement related to a novel class of poly-receptor active opioid-like drug candidates targeting pain and substance abuse and addiction treatment.

Under the terms of the deal, Aoxing (which, though USA-headquartered, has its main operations in China) and PPL (a Utah-based clinical-stage drug discover firm) entered into a multi-party collaboration agreement for the development and regulatory approval of a novel class of therapeutics in both China and ex-China territories. The two companies will continue to co-collaborate with the US National Institute of Drug Abuse (NIDA) and the Chinese National Institute on Drug Dependence at Beijing University (NIDD).

Aoixing gets rights for China, Macau and HK

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK